Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Adaptive Design Trial of Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors

NCT02537561 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT02537561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02537561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Adaptive Design Trial of Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Withdrawn
Start date
December 31, 2015
Completion date
December 31, 2018
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, non-small cell lung cancer, non-small-cell lung carcinoma, nonsmall cell lung cancer, solid tumors